₦airaland Forum

aremso:
I think biotechs PH3 trials would be fantastic in the long run ENSC some hedgeies have been positioning since about 2 weeks ago with, 3 firm have taken up about 28% of the biotech company now. If their PH3 is successful the stock can do 1500% though nasdaq gave them 19th of December to hit 1$+ if the stock can get over 1$ and beat nasdaq wahala with success of PH3 trial+ FDA approval then it can do 10-25$ with time. Am still holding at 94% it was even 124% before the pull back I will hold till next year by God grace for the outcome of their clinical trials of PH3 then subsequent FDA approvals.

Health stocks will always carry 90% of my portfolio

You are one hundred percent correct

YellowbaMoslem:
Digging his own grave?

You mean the women would kill him?

hahahaha, don't you know women kills faster than poison

tanigororo:
Bamboo on Kuda

Bamboo yes,Kuda,no.
.
I uses Bamboo, but Kuda is not a broker,it's an online bank like opay
.
Register with bamboo and get back to me and will put you through

WebLab:
Thank you for your contribution boss. Please, do you have any bank most profitable in terms of foreign shares purchase?

you do not buy through the bank,you use a broker that deals on foreign shares

Miss Denmark Victoria Kjær Theilvig has been crowned Miss Universe 2024 after competing against 125 contestants (down from 130 due to withdrawals and disqualifications) during the final night of the 73rd annual Miss Universe competition held in Mexico City. Her triumph was the result of an eventful, emotional pageant.


The Danish beauty queen, a European and World Championship dancer, captivated the judges and audience with her poise and eloquence. A beauty entrepreneur, mental health advocate, protector of animals, and aspiring lawyer, Victoria proved that the title of Miss Universe goes beyond physical beauty. Her responses in the question-and-answer segment resonated deeply with the global audience.

As the first Miss Universe winner from Denmark and the first European in years, Victoria used her platform to highlight her passion projects. Her advocacy for mental health and animal protection has already gained international recognition.


Victoria's reign as Miss Universe is expected to focus on global initiatives that align with her passions, blending her legal aspirations with her commitment to empowering others. Her win is a celebration of Denmark and proof of the values of empathy, strength, and leadership she represents.

WebLab:
Hello everyone,

Please, I need your advice on any business I can do with 1 Million Naira. The truth is that I need a side hussle to get me more money other than my job. The economy is biting hard and I need to expand the horizon of my income flow.

I have thought of getting a bike for someone who will be making delivery on daily basis but I am not sure if it's a wise decision. I am thinking of POS business center where I can put someone to manage. I am just a bit confused.

Please, your suggestion and advise will be appreciated.

Thanks in advance.

Since you are still working, you don't need to open a business that you won't be there all the time, because it will surely crumble,due to a lot of factors.

Having said that,I will advise you to put your money into buying and selling of foreign shares, you will be amazed at the ROI, with rest of mind

Creamypie:
This na our close friend for orogun

It's their grandparents in orogun and not friends

Please expantiate

Lucifyre:
Says the retard that doesn't get nuance. Go sit in the corner oaf.

you deliberately refused to be wise

It was a mistake,in so far it has been corrected

Switinthemiddle:
Why do we always term "bad" things like porn, alcohol, gambling and all sorts as addiction... Can't other things like.. reading. Watching movies,tiktok and picking of one's nose an addiction. ..
Let's change our mindset... These things we always term as addiction are other people's source of income in other countries...

alcoholism kills, gambling leave you bankrupt but the companies in these industries are reaping millions from people addiction,so it's an individual decision to make wheather to waste your life or not.

On the other hand the other addiction you mentioned is a fifty fifty advantage unlike porn, alcoholism, gambling, womanizer etc

The South-South Initiative for Better Nigeria has commended President Bola Tinubu for three key appointments in the Nigerian National Petroleum Company Limited (NNPCL).
In a statement signed by the National Coordinator of SSIBN, Mr Jack Akpvwoghene and Programs Manager, Ebitare Wellington, the group praised the President for his commitment to the development of the Nigerian oil sector.
It said the recent appointments into key management positions of the NNPCL demonstrate the president’s resolve to strengthen the company’s operational efficiency and boost its competitive edge in the global oil and gas industry.
“These significant appointments are a testament to your unwavering commitment to the Nigeria oil and gas sector in ensuring it meets international standards and boosts Nigeria’s potential as far as the Oil and Gas Industry is concerned.
“As we celebrate these appointments, we look forward to their continued efforts in driving impactful policies and programs that will further uplift the oil and gas sector of the country”, it said.

“The appointments of Mr. Isiyaku Abdullahi as Executive Vice President, Downstream, Mr Udobong Ntia as the Executive Vice President Upstream, and Mr. Adedapo A. Segun, appointed as the Chief Financial Officer (CFO) cannot come at a time other than now as it shows the unwavering support of Mr. President in taking the Nigeria Oil and Gas sector to a greater height in the global Oil and Gas industry,” the statement said.
The appointment of Ntia Udobong Kokoete could not have come at a better time as it reminds us in the South South of the good days of Adokiye Tombomieye as EVP upstream who was able to manage internal affairs of the Niger Delta region, helping the GCEO, Mele Kolo Kyari to have a smooth relationship with youths in the region.
“We at SSIBN commend Mr. President for these key major appointments in the oil sector and we stand ready to support him as well as collaborate with him on initiatives that align with the vision of a prosperous and inclusive Nigeria”, he said.








Founded on January 22, 1995, THISDAY is published by THISDAY NEWSPAPERS LTD., 35 Creek Road Apapa, Lagos, Nigeria

b0rn2fuck:
I Bleep a Mother of 41 years old which happened to be a married woman and same time she is my secret lover and her daughter which is just 20 years of age , I even Bleep the woman friend whom was also another married which age is 38 years old ..


Sometimes I think over it and laugh, sometimes I felt bad

you are daringly adventurous, you went too far,if you continue this way,I am afraid you are digging your own grave

1. RECOGNIZE THE PROBLEM

Before overcoming any addictions, you need to acknowledge that you have a problem.

I know it is hard to accept it but it is necessary to do it.

It can be:

• Porn
• Weed
• Alcohol
. Gambling
You can also ask your friends or family to help you.

2. EDUCATE YOURSELF

Educating yourself about the addiction is necessary.

Research for:

• Why does this addiction happens?
• Side effects of your addiction
• How can you quit it?

There are a lot of resource available online that you can look for.

Addiction is a mindset.

3. IDENTIFY THE ROOT CAUSE

If you don't know the root cause of your addiction, you won't be able to quit it.

The underlying issue can be:

• Stress
• Trauma
• Anxiety
• Depression
• Toxic Relationships

Address the underlying issue and develop strategies to overcome it.


4. PRACTICE MINDFULNESS

Mindfulness is a practice of living in the present moment.

Start analysing your:

• Thoughts
• Feelings

Being self aware of yourself can help you save yourself from these addictions.

Mental Clarity > External Motivation

5. FIND YOUR PURPOSE

Majority of addicts don't have a sense of purpose in their life.

This leads to stress and anxiety because they are not sure what they want to do.

You might be facing the same problem.

Pursue your passion and do what you love.

The year is winding down, but the bull markets are still charging ahead, getting a boost from improved sentiment after the presidential election. While the next few months will be a time of transition, a few things are likely. The Trump administration is expected to pursue a far looser regulatory policy than the outgoing Biden government. Plans for individual tax cuts are projected to drive consumer spending, while reductions in corporate taxes could deliver an immediate boost to earnings.

While recent market gains are largely driven by blue-chip giants, penny stocks quietly attract investors seeking untapped growth opportunities. Priced below $5 per share, the penny stocks offer a unique blend of risk and reward, with the potential to double or even triple initial investments.

The nature of these investments presents somewhat of a dilemma. How are investors supposed to separate the penny stocks that are ready to take off on an upward trajectory from those set to remain down in the dumps? This is where Wall Street’s analysts come into play.

We used the TipRanks database to uncover two compelling penny stocks that have earned Strong Buy ratings from the analyst community. According to the pros, these tickers are set to triple or more in the coming year. Let’s take a closer look.

Genelux Corporation (GNLX)

The first penny stock in the spotlight is Genelux, a clinical-stage biotech working in the world of immuno-oncology. Genelux’s research program is focused on the development of the next generation of cancer treatments, using oncolytic virotherapies to create therapeutic agents that can target a wide range of cancers. The company uses vaccinia virus to selectively replicate inside tumor cells and to kill them – while leaving the patient’s normal cells intact.

Genelux’s drug candidates target some of the more difficult-to-treat cancers, including a wide range of dangerous solid tumors, and are developed using the company’s CHOICE discovery platform. This is a proprietary platform that allows for the quick progression of new treatment candidates from early discovery through the clinical trial stages. Using its platform, Genelux has developed its leading oncolytic immunotherapy candidate, Olvi-Vec.

Olvi-Vec has been the subject of several early- and mid-phase clinical trials, but the current excitement around the drug candidate comes from the ongoing Phase 3 trial of the drug as an intraperitoneal (IPe) dosed treatment for platinum-resistant/refractory ovarian cancer (PRROC), a disease that is difficult to treat and has high unmet medical needs. The current Phase 3 trial will enroll up to 186 patients, and the company expects to release topline results in 2H25.

In addition to PRROC track, Genelux also has Olvi-Vec undergoing a Phase 2 trial in the treatment of non-small cell lung cancer (NSCLC). The interim readout for this trial is expected in the middle of next year.

Given these potential clinical milestones and GNLX’s current share price of $2.63, several members of the Street think that now is the right time to pull the trigger.

Roth MKM analyst Benjamin Paluch is particularly upbeat, suggesting that the Phase 3 ovarian cancer trial has the potential to be a game-changer for the stock.

“We view topline results from the Phase 3 study of Olvi-Vec in platinum resistant/refractory ovarian cancer as the key catalyst for the stock. Our base case is the trial is successful and shows a statistically significant progression-free survival (PFS)… Our base case assumes 70% upside with potential for a 100% gain under our bull case scenario and downside potentially limited to 30% under our bear case scenario… Recall, the FDA granted Fast Track designation to Olvi-Vec in platinum resistant/refractory ovarian cancer in November 2023, which suggests to us that the FDA could be flexible with its review, particularly in platinum refractory patients for which therapeutic options are limited,” Paluch opined.

To this end, Paluch rates GNLX a Buy along with a $10 price target. Should his thesis play out, a potential gain of 277% could be in the cards. (To watch Paluch’s track record, click here)

Other analysts don’t beg to differ. 4 Buy ratings and no Holds or Sells have been assigned in the last three months. Therefore, GNLX is a Strong Buy. The $15 average price target implies shares could climb 470% higher in the coming year. (See GNLX stock forecast)


SAB Biotherapeutics (SABS)

The next stock we’ll look at here is another biotherapeutic firm, SAB. This company has a focus on the treatment and prevention of immune and autoimmune diseases, a class of disease conditions that are known for the difficulties they present to both patients and care providers, in the form of dangerous symptoms and resistance to treatment.

SAB has developed an innovative genetic engineering platform, which it uses in the creation of new therapeutic agents. The company aims to develop multi-targeted, high-potency immunoglobulins (IgGs), and to do so without requiring human donors or even the use of convalescent plasma. While every biotech firm likes to say that it is unique, SAB is currently the only company on the scene capable of producing a truly polyclonal human antibody sans donor. These antibodies can be used to target diseases that present serious health challenges.

The company’s leading drug candidate, SAB-142, is a potential blockbuster if it pans out. SAB-142 offers a new approach to the treatment of type 1 diabetes (T1D), through disease modification. This drug candidate is a novel therapy for T1D, being a potentially redosable human antibody under study for its ability to delay the onset of clinical signs in, or the progression of, type 1 diabetes. SAB-142 is not insulin, nor would it require daily monitoring or management; in fact, the company sees a high chance that the drug could be administered on a one-yearly regimen.

In May of this year, SAB Biotherapeutics received clearance from the FDA to begin Phase 1 clinical testing of SAB-142 in the US. Enrollment for the Phase 1 trial has been completed, and the company expects to have a data readout by the end of this year. Early data showed no observation of serum sickness in the enrolled patients. SAB also has a Phase 1 trial underway in Australia, and expects to provide a data readout by year’s end.

These developments have drawn attention from Craig-Hallum analyst Albert Lowe, who has taken a closer look at the stock.

“We believe the company’s unique ability to produce human polyclonal antibodies (pAbs) offers profound opportunities for developing novel therapies, led by SAB-142. SAB-142 has a clear value proposition that builds on rabbit ATG’s (rATG) clinically validated mechanism of action in delaying the onset of T1D. As a human ATG, SAB-142 overcomes the safety limitations of rabbit ATG, making it a redosable disease-modifying therapy that enables long-term T1D disease prevention. We see opportunity for share appreciation as SAB-142 proceeds through development, where clinical data gives us confidence that SAB-142 can be the best-in-class therapy for long-term T1D prevention,” Lowe wrote.

In line with his optimistic take, Lowe rates SABS a Buy and set a price target of $11, which implies a potential upside of 237%. (To watch Lowe’s track record, click here)

Overall, all four of the recent analyst reviews on SABS are positive, making the Strong Buy consensus unanimous. The stock’s $3.26 trading price and $13.50 average target price combine to imply a 323% upside on the one-year horizon. (See SABS stock forecast)


To find good ideas for penny stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a tool that unites all of TipRanks’ equity insights.

Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

The chances of beating a sitting governor in Nigeria is 1 over 100

Pot calling kettle black

APOPTOSIS:
You call this being resourceful...😰😰🙆🏾‍♂️🙆🏾‍♂️

what is it

Lucifyre:
Like i said it obviously paints the full pic of your iq, cause nuance doesn't exist in your brain cells.

Stop typing rubbish,not to allow people to doubt your sanity, which you have proved in many of your post

essentialone:
Re-arrange the following according to how Useless and Irrelevant they are to you, starting with the most useless:

A: Traditional Rulers
B: House of Reps Members
C: Local Government Area Chairmen
D: Local Government Ward Councillors

No one is useless or irrelevant, think out of the box you will begin to see their usefulness.

Penboy:
You subscribe to Motley fool?

yes

Lucifyre:
You step up your comprehension, cause it's badly lagging. He did not deride education in any way shape or form, says much about your own 'IQ'.

he said education is a scam,is he not deriding education by this comment, you lacked serious comprehension

nolzautoz:
Nothing wey our eye never see for naija. This is simply telling people education is a scam as Naija now wan dey award DJ. When una go start to dey honor intellectual people wey dey contribute positively to the society. No be the ones wey dey instigate prostitution that leads to HIV. Award for DJ, Nna Mhen

O boy please step up your IQ, education is not a scam,most of the top DJ's and AOP in the country are graduates.

Without a good education you cannot Excel in thls and other fields and endeavors

Academic excellence is still being rewarded across the country

HellVictorinho9:
can u help me with murny pls?


9163989689

opay

thanks

month end I promise to send something to you

Tensions between Israel and Iran have led to multiple attacks on each other over recent months. In the latest incident, Israel launched attacks on several Iranian military and strategic sites on October 26, resulting in the deaths of five people, including a civilian

Tensions between Iran and Israel have not eased. Although Iran has yet to respond to Israel’s attack on October 26, the risk of conflict between the two countries remains high. In the meantime, Iran has initiated significant preparations for a potential war with Israel. According to state media, Iran is constructing its first defensive tunnel. The tunnel, located near the city centre, will link a station on the Tehran metro to the Imam Khomeini hospital, thus allowing direct underground access to the medical facility.” For the first time in the country, a tunnel with defensive applications is being built in Tehran,” the head of transport for Tehran City Council told Reuters. Last year, there were also reports about Iran building underground shelters and bunkers.

Last month, Israel carried out its first officially recognized strikes in Iran, hitting missile factories, air defenses and other sites near Tehran and in the country’s west, as a response to Iran’s October 1 ballistic missile attack on Israel.

Iran’s first defensive tunnel
According to reports, this defensive tunnel in Tehran will directly connect the city center to Imam Khomeini Hospital. Hamshahri News states that this is the country’s first defensive tunnel project, designed as an underground passage from a metro station directly to Imam Khomeini Hospital. In case of war, this underground tunnel could be used for medical facilities. The head of transportation for Tehran’s City Council has indicated that, for the first time, a tunnel with defensive applications is being constructed in the capital.

Iran’s underground shelters
Last year, Iran’s state media released video footage showing images of Iran’s underground shelters and bunkers. These shelters and bunkers were constructed to house Iran’s air defense systems and weapons. It was the first time that Iran publicly released images of these defense system locations.

Possibility of full-scale war with Israel
Tensions between Israel and Iran have led to multiple attacks on each other over recent months. In the latest incident, Israel launched attacks on several Iranian military and strategic sites on October 26, resulting in the deaths of five people, including a civilian. Israel claimed the attacks were in retaliation for an assault earlier in October.

In response, Iran is once again preparing for a counterattack, labeling the October 26 strikes as an assault on Iranian sovereignty. Meanwhile, Israel has warned Iran that if it retaliates, Israel will target additional sites that were left untouched in the previous attack. With tensions remaining high, there is growing concern that the situation could escalate into a full-scale war.
India.com

blacknp:
Just imagine, to even make matters worse, the nonsense is null & void ab initio.

I no blame u.

no information is nullified and void,if not now,it can be used for posterity

blacknp:
Nonsense.

There is sense in every nonsense

A Heartbreaking and Untold Story:

Yakubu Gowon, Nigeria’s former Head of State, was only 31 when he assumed power. At the time, he was in a relationship with Edith Ike, an Igbo woman, who was by his side even during the turmoil of the January 15, 1966 coup led by Major Emmanuel Ifeajuna and other conspirators. Their relationship held strong despite the political tension that gripped the nation.

However, following the assassination of General Aguiyi-Ironsi in July 1966 and the subsequent violence against Igbo soldiers and civilians, Gowon faced immense pressure and distrust from within the Northern military ranks and beyond. The escalating anti-Igbo sentiment placed him in a position where his relationship with Edith was scrutinized and criticized. Overwhelmed by the situation, Gowon’s trust in Edith began to wane, and the relationship couldn’t withstand the intense national crisis. In 1972, at the age of 34, Gowon moved on and married Victoria Zakari, and they recently celebrated their 55th wedding anniversary in Abuja.

In a later development, Edith claimed that Gowon was the father of her son, Musa, born a year before his marriage to Victoria. After a legal battle that reached the Supreme Court, the ruling was in Edith’s favor, yet Gowon denied paternity. It wasn’t until 2016, after a DNA test confirmed his paternity, that Gowon finally acknowledged Musa Jack Ngodadi Gowon as his son. At the time, Musa had just been released from a U.S. prison after serving 23 years for a drug-related offense, and he was 47 years old.

Tragically, Edith passed away from breast cancer in 2003 while her son was still behind bars, leaving a legacy marked by personal and political heartbreak.

The story of Gowon, Edith, and Musa serves as a reminder of the human cost of Nigeria’s turbulent history, where personal relationships were often shattered by the forces of political and ethnic conflict.

Source: historylovers

---

For more historical insights and untold stories, follow us:
Instagram: @tvauthorityng
Twitter: @tvauthorityng
Facebook: TV Authority

Nigeria has qualified for the 2025 AFCON in Morocco with two games to spare, thanks to Libya’s 1-0 victory over Rwanda in Kigali on Thursday, The PUNCH reports.

The Mediterranean Knights stunned their hosts with an 84th-minute goal from Saad Mohamed, reviving their own chances of qualifying for the tournament in Morocco and ultimately securing Nigeria’s place in the 35th
AFCON tournament next year.

The Super Eagles were scheduled to face the Cheetahs of Benin Republic at the Stade Felix Houphouet-Boigny in Abidjan, Ivory Coast, needing at least a point to secure their spot in Morocco. However, Libya’s victory ensured Nigeria’s qualification before kick-off, sparing them the pressure of needing a result. Libya had put the Nigerian team through an unforgettable ordeal in October.

Nigeria, three-time African champions, have now qualified for their 21st appearance at the tournament, which will take place from December 21, 2025, to January 18, 2026.

Libya deliver Eagles 2025 AFCON ticket
The Super Eagles recently finished as runners-up in the 2023 edition, held between January and February this year in Ivory Coast. The team, managed by Portuguese coach Jose Peseiro, lost 2-1 to the hosts in the final, marking Nigeria’s fifth agonising defeat in an AFCON final since their first participation in 1963. They have also finished third on eight occasions.

Nigeria’s three AFCON titles were won on home soil in 1980, in Tunisia in 1994, and in South Africa in 2013.

Libya’s win means the Super Eagles now only need a draw to secure the top spot in the group, with their match against Rwanda still to come at the Godswill Akpabio International Stadium in Uyo on Monday.

As things stand in Group D, third-placed Rwanda, with five points, and bottom-placed Libya, one point behind them, still have slim hopes of qualifying for the tournament.


punchng.com © 1971- 2024 Punch Nigeria Limited

2 Stocks That Could Create Lasting Generational Wealth


Patience should pay off if investors hold these businesses over many years.
Both companies have been paying dividends for decades.
Motley Fool Issues Rare “All In” Buy Alert
Time is on your side with these successful stocks.

If you're looking to create enduring wealth, the stock market is a great place to focus your attention. Businesses can grow their earnings power for decades, and some of the best companies have been rewarding shareholders with positive returns for over a century. Consider a company like Procter & Gamble, which has been paying out a dividend since the 90s -- the 1890s, that is.

Yet it's a challenge to identify stocks that can maintain their strong market positions for many decades, and there's always the risk of a major industry or technology shift impairing a previously successful business. That's why it pays to construct a portfolio of several world-class businesses. That way you aren't too dependent on any single company.

With that in mind, let's look at a few stocks that, from today's vantage point, seem poised to produce wealth over the long term.

1. Walmart
Walmart (WMT -0.04%) has been creating millionaires (beyond just the Walton family) for many generations. But there's plenty of room for this retailing giant to extend that momentum. Just take a look at the latest financial results that show how the company is winning with its core shoppers while extending into new markets and demographics.

NYSE: WMT
Walmart
Today's Change
(-0.04%) -US$0.04
Current Price
US$84.43
Customer traffic was up 4% year over year this past quarter even as average spending rose 1%. The e-commerce segment jumped 22%. That division is already worth over $100 billion in annual sales and is bringing more high-income shoppers into the Walmart brand. You can bet management will lean heavily on growth there to keep pushing earnings higher in the coming years. Walmart is also investing aggressively in digital advertising, which has been a big source of income for rival Amazon.

Those growth initiatives help explain why Walmart pays a modest dividend yield of below 1% as of mid-November. Yet investors who hold this stock for decades should benefit from the company's aggressive spending in those attractive categories.

2. McCormick
McCormick (MKC -2.63%) hasn't had the best post-pandemic period, yet that's no reason to avoid the stock for this consumer foods producer. It dominates several attractive categories in the spice, flavorings, and sauces niches with global brands like Cholula, Old Bay, and French's. That premium market position has helped it protect profit margins despite having to pass along higher prices to consumers over the past two years and dampening demand in the process.


Those price hikes have slowed to a crawl along with McCormick's decelerating costs in recent quarters. In Q3, the company returned to global volume growth as average selling prices declined slightly. "We expect this momentum to continue into the fourth quarter," CEO Brendan Foley said in an early October press release.

Sure, the 3% sales uptick that most Wall Street analysts expect in 2025 doesn't sound exciting. You could find faster organic growth from rivals like PepsiCo, which also happens to pay a higher dividend yield today.



NYSE: MKC
McCormick
Today's Change
(-2.63%) -US$1.97
Current Price
US$72.95
McCormick's more focused portfolio, though, should pave the way for many more years of market share growth and improving profitability. That's a recipe for market-beating returns from here for a stock that's trailed the market through the 2024 rally.

If you're concerned about the timing of McCormick's rebound, you might want to watch the next few quarterly reports for concrete signs that the business is again ready to grow both sales volumes and average prices. Yet patient investors focused on the long term should consider adding the food specialist to their portfolios while there's still some uncertainty keeping its valuation relatively low.




© 1995 - 2024 The Motley Fool. All rights reserved.

illicit:
So what's the similarity...

Both of them speaks without reasoning

The FBI, CIA, and DEA face legal scrutiny as they invoke Glomar responses—provisions allowing them to withhold confirmation of records to protect privacy and national security—amid requests for information on Nigerian President Bola Tinubu’s alleged ties to drug trafficking.

In a recent court filing, the agencies argued that confirming or denying the existence of records could compromise privacy interests and national security, as they responded to multiple Freedom of Information Act (FOIA) requests from plaintiff Aaron Greenspan. The case highlights ongoing tensions between transparency and the protection of sensitive information held by federal agencies.

The CIA, FBI, and DEA jointly filed a statement opposing the release of unredacted files on Tinubu’s background, again citing national security concerns. According to the filing, disclosing these details could endanger U.S. interests abroad.

Court documents from a Chicago case claim that in the early 1990s, Tinubu was linked to bank accounts allegedly used to launder money for a heroin ring in Chicago. Records from 1993 reveal that Tinubu, then a prominent figure in Lagos, agreed to forfeit assets to U.S. authorities in a plea bargain, sidestepping a potential trial on drug trafficking and money laundering charges.

Nigerian journalist David Hundeyin, a vocal advocate for transparency on the issue, posted on X (formerly Twitter) that the CIA, FBI, and DEA had recently submitted a memorandum opposing the release of Tinubu’s records. Intelligence officials argued that revealing such connections could “compromise U.S. national security” and referenced Tinubu’s possible status as a CIA asset.

Amid public demands for transparency, the DEA echoed the CIA’s stance, maintaining that citizens are not entitled to unrestricted access to intelligence files. “We oppose the full, unredacted release of the DEA’s Bola Tinubu heroin trafficking investigation records because… they do not have a right to know what their president is up to,” the DEA stated.

The agencies' position hinges on national security risks, with the CIA underscoring the potential consequences of either confirming or denying any ties to Tinubu.

Hundeyin expressed frustration with what he described as the U.S. intelligence community’s support for “terrible leaders” in Africa, accusing it of worsening regional instability.

It has been 31 years since Tinubu, then a private citizen, forfeited $460,000 to U.S. authorities after an investigation tied him to alleged drug trafficking in Chicago.

Meanwhile, Dada Olusegun, Tinubu’s special assistant on social media, dismissed the claims of CIA ties as “tragic” and baseless, asserting the president’s innocence.


© 2024 OCCRP
Privacy Policy